Results 51 to 60 of about 1,955 (223)

Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy

Frontiers in Endocrinology, 2022
An inactivating PHEX gene mutation with the resultant accumulation of several mineralization-inhibiting proteins (e.g., FGF23) causes skeletal and dental morbidity in X-linked hypophosphatemia (XLH).
Rafi Brener, Rafi Brener, Leonid Zeitlin, Leonid Zeitlin, Yael Lebenthal, Yael Lebenthal, Avivit Brener, Avivit Brener   +7 more
doaj   +1 more source

BUROSUMAB IN TUMOR-INDUCED OSTEOMALACIA [PDF]

, 2021
Patients with tumor-induced osteomalacia (TIO), an acquired paraneoplastic condition characterized by osteomalacia due to hypophosphatemia, exhibit a similar clinical picture to those with X-linked hypophosphatemic rickets/osteomalacia (XLH).
Fukumoto, Seiji, Imanishi, Yasuo, Ito, Nobuaki, Kanda, Hironori, Kanematsu, Masanori, Kojima, Masahiro, Onuma, Hiroki, Rhee, Yumie, Seino, Yoshiki, Shin, Chan Soo, Takahashi, Yutaka, Takeuchi, Yasuhiro   +11 more
core  

Tumor induced osteomalacia: a systematic review and individual patient's data analysis [PDF]

, 2022
Context: Tumor induced osteomalacia (TIO) is a rare paraneoplastic syndrome, usually caused by small, benign and slow-growing phosphaturic mesenchymal tumors.
Abate, Veronica, Cacace, Giuseppe, Cuocolo, Alberto, D'Elia, Lanfranco, D'Elia, Lanfranco, De Filippo, Gianpaolo, Del Vecchio, Silvana, Galletti, Ferruccio, Rendina, Domenico, Strazzullo, Pasquale   +9 more
core   +1 more source

Health-related quality of life of X-linked hypophosphatemia in Spain [PDF]

, 2022
Burden of disease; Health-related quality of life; X-linked hypophosphatemiaCarga de la enfermedad; Calidad de vida relacionada con la salud; Hipofosfatemia ligada al cromosoma XCàrrega de la malaltia; Qualitat de vida relacionada amb la salut ...
Ariceta Iraola, Gema, Diaz-Curiel, Manuel, Luis Yanes, Maria Isabel, Marin, S., Peris, P., Ramon-Krauel, Marta, Vicente, C.   +6 more
core   +1 more source

Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review

Archives of Endocrinology and Metabolism
Burosumab, a monoclonal antibody directed against the fibroblast growth factor 23 (FGF23), has been approved for the treatment of X-linked hypophosphatemia (XLH).
Manjunath Havalappa Dodamani, Samantha Cheryl Kumar, Samiksha Bhattacharjee, Rohit Barnabas, Sandeep Kumar, Anurag Ranjan Lila, Saba Samad Memon, Manjiri Karlekar, Virendra A. Patil, Tushar R. Bandgar   +9 more
doaj   +1 more source

Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy

Therapeutic Advances in Endocrinology and Metabolism, 2021
Background: Burosumab, a recombinant anti-FGF23 monoclonal antibody, was recently introduced as a treatment for X-linked hypophosphatemia (XLH). Burosumab normalizes blood phosphate levels, thereby healing rickets, decreasing leg bowing, and reducing ...
Avivit Brener, Yael Lebenthal, Roxana Cleper, Livia Kapusta, Leonid Zeitlin   +4 more
doaj   +1 more source

Burosumab - a new drug to treat hypophosphatemic rickets [PDF]

Sudanese Journal of Paediatrics, 2017
Burosumab (KRN23) is a fully human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets. A report enclosed in this letter gives a brief review of current knowledge on burosumab therapy.
Stepan Kutilek, Dr. Babiker, Dr. Alenazi
openaire   +2 more sources

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children

Frontiers in Endocrinology, 2020
Burosumab (KRN23) is an FGF23 neutralizing antibody that has been the subject of several recent clinical trials principally focused on the treatment of hypophosphatemic rickets in patients with X-linked hypophosphatemia (XLH).
Aaron Schindeler, Aaron Schindeler, Andrew Biggin, Andrew Biggin, Craig F. Munns, Craig F. Munns   +5 more
doaj   +1 more source

Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium

Frontiers in Endocrinology, 2021
X-linked hypophosphatemia (XLH) is the most common genetic form of hypophosphatemic rickets and osteomalacia. In this disease, mutations in the PHEX gene lead to elevated levels of the hormone fibroblast growth factor 23 (FGF23), resulting in renal ...
Michaël R. Laurent, Jean De Schepper, Jean De Schepper, Dominique Trouet, Dominique Trouet, Nathalie Godefroid, Emese Boros, Claudine Heinrichs, Bert Bravenboer, Brigitte Velkeniers, Johan Lammens, Pol Harvengt, Etienne Cavalier, Jean-François Kaux, Jacques Lombet, Kathleen De Waele, Charlotte Verroken, Koenraad van Hoeck, Koenraad van Hoeck, Geert R. Mortier, Elena Levtchenko, Johan Vande Walle   +21 more
doaj   +1 more source

Molecular pathophysiology of chronic kidney disease–mineral and bone disorder: Focus on the fibroblast growth factor 23–Klotho axis and bone turnover dynamics

Experimental Physiology, EarlyView.
Abstract Chronic kidney disease–mineral and bone disorder (CKD‐MBD) is a major complication of chronic kidney disease (CKD), characterized by disruptions in mineral metabolism, abnormal bone turnover and vascular calcification, which collectively increase the risk of fractures and cardiovascular disease.
Alief Waitupu, Laras Pratiwi, Henry Sutanto, Djoko Santoso, Decsa Medika Hertanto   +4 more
wiley   +1 more source